Innovative Drug Delivery And Development

Innovative Drug Delivery And Development

Innovative drug delivery and development Robert Davidson Chief Executive Officer of CURE. CURE Pharmaceutical is an innovative drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry-leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system, the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel, and Germany, among other markets.

Innovative Drug Delivery And Development

Robert Davidson is CURE’s CEO. Prior to his role at CURE Pharmaceutical, Robert Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic, Suppress, as well as Pediatric, a private label electrolyte oral thin film sold in major drug store chains. Mr. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also completed his Post Graduate Studies at the University of Cambridge with letter of commendation.